Diabetes Drugs Like Wegovy and Zepbound Revolutionize Weight Loss

Medications originally designed for diabetes are now making headlines for their weight-loss benefits. Drugs like Wegovy, Ozempic and Zepbound have surged in popularity as demand grows for effective obesity treatments. Recent studies highlight their varying success in helping people shed excess weight. Wegovy, a once-weekly stomach injection, has been approved specifically for weight loss in adults with obesity (a BMI of 30 or higher) or those with a BMI of 27 or higher alongside weight-related health issues. Research shows it outperforms both placebos and other antidiabetic drugs in reducing body weight. Its active ingredient, semaglutide, is also sold under the brand name Ozempic—but Ozempic itself is only officially prescribed for type 2 diabetes patients at risk of heart problems, not for weight loss.

Tirzepatide, marketed as Mounjaro for diabetes and later as Zepbound for obesity, received FDA approval for chronic weight management in November 2023. Initially greenlit for diabetes in May 2022, its expanded use marks a shift from blood sugar control to broader obesity treatment. In separate studies, higher doses of tirzepatide (10 mg and 15 mg) proved more effective than Wegovy, though the comparison was not direct.

Another option, liraglutide (Saxenda), is available for weight loss in people aged 12 and older with obesity or overweight. Meanwhile, Botox—unrelated to GLP-1 drugs—has shown inconsistent results in weight-loss research. The growing interest in GLP-1 agonists reflects their proven effectiveness in clinical trials. Wegovy, Zepbound and Saxenda now offer approved options for long-term weight management, while Ozempic remains limited to diabetes care. As demand rises, these medications continue to reshape obesity treatment.